All News

9 February 2009

Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Antibodies

6 February 2009

UCB’s meeting with U.S. FDA defines path forward for Cimzia(R) in rheumatoid arthritisAntibodies

5 February 2009

GlaxoSmithKile and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood CancerAntibodies

5 February 2009

Ablynx Announces Second Extension of its Nanobody(R) Drug Discovery and Development AlianceAntibodies

5 February 2009

Dyax Announces Expansion of Antibody Discovery Collaboration with Biogen IdecAntibodies

4 February 2009

Peregrine Pharmaceuticals’ Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer StudyAntibodies

3 February 2009

ESBATech’s Antibody Fragment Enters Phase Ib/IIa in OphthalmologyAntibodies

2 February 2009

Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546Antibodies

30 January 2009

GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancerAntibodies

28 January 2009

Goodwin Biotechnology, Inc. Completes GMP Manufacturing of Neogenix Oncology, Inc. Monoclonal Antibody for Upcoming Clinical TrialsAntibodies

28 January 2009

Medarex Announces Allowance of Investigational New Drug Application for Company’s First Antibody-Drug Conjugate, MDX-1203Antibodies

26 January 2009

BioInvent and ThromboGenics Receive Technology Transfer Success Fee from Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)Antibodies

26 January 2009

Selexys Pharmaceutical Corporation and Cytovance(R) Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)Antibodies

26 January 2009

Access Pharmaceuticals Presents new Combination Data on the Company s Angiolix(R) Therapeutic Monoclonal AntibodyAntibodies

26 January 2009

ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)Antibodies

22 January 2009

Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel DiseaseAntibodies

22 January 2009

RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid ArthritisAntibodies

22 January 2009

New Biologic Stelara(R) Receives Approval in Europe for Treatment of Moderate to Severe Plaque PsoriasisAntibodies

22 January 2009

ZEVALIN(R) Produced 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma StudyAntibodies

22 January 2009

XOMA Receives Milestone Payment From Pfizer Under Antibody Technology LicenseAntibodies

21 January 2009

Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin LymphomaAntibodies

20 January 2009

Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal CancerAntibodies

19 January 2009

MorphoSys Provides Update on Pipeline Activities in 2009Antibodies

14 January 2009

Cephalon Signs Option Agreement to Acquire Ception TherapeuticsAntibodies

14 January 2009

Merck KGaA: New Data Reinforce Consistent Efficacy Profile of Erbitux in First-Line mCRC Patients with KRAS Wild-Type TumorsAntibodies

14 January 2009

Ablynx Announces Technical Advances in its Nanobody(R) Platform Technology: Enhanced Benefits from Pulmonary Delivery and Half-Life ExtensionAntibodies

13 January 2009

InNexus Biotechnology Completes Preclinical Study Confirming In Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting with FDAAntibodies

12 January 2009

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AGAntibodies

9 January 2009

ESBATech’s Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying ActivityAntibodies

6 January 2009

YM Bioscience Receives Clearance to Initiate Randomized Double-Blind Clinical Trials of Nimotuzumab in Lung Cancer and Brain Metastases form Lung CancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TSLP Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis